{"schema_version":"secwatch.filing_event.v1","accession":"0000917520-23-000069","form_type":"8-K","ticker":"IART","cik":"0000917520","company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","filed_at":"2023-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.396081+00:00","generated_at":"2026-06-09T12:56:53.518479+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Integra Q3 revenues down 0.7%, GAAP EPS $0.24; adjusts FY23 guidance lower","bullets":["Q3 revenue $382.4M, reported -0.7% YoY; organic ex-Boston +7.1%.","GAAP EPS $0.24 vs $0.60; adjusted EPS $0.76 vs $0.86.","Codman Specialty Surgical +7.4% organic; Tissue Technologies -15.1% organic due to Boston recall returns.","FY23 revenue guidance cut to $1.541-1.547B; adjusted EPS $3.10-3.14.","Boston facility restart on track for Q4'23; commercial distribution expected mid-to-late Q2'24."],"urls":{"canonical":"https://secwatch.observer/filing/0000917520-23-000069","json":"https://secwatch.observer/filing/0000917520-23-000069.json","markdown":"https://secwatch.observer/filing/0000917520-23-000069.md","text":"https://secwatch.observer/filing/0000917520-23-000069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/917520/000091752023000069/0000917520-23-000069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/917520/000091752023000069/iart-20231025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T12:56:53.518479+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6d269066a944bc4732968e12f1eda79c95fc107e","claim":"INTEGRA LIFESCIENCES HOLDINGS CORP reported third quarter ending September 30, 2023 results: revenue $382.4 million, net income $19.5 million, EPS $0.24 per diluted share.","evidence_excerpt":"global medical technology company, today reported financial results for the third quarter ending September 30, 2023. Third Quarter 2023 Highlights • Third quarter revenues of $382.4 million declined 0.7% on a reported basis and declined 0.4% on an organic basis compared to the prior year and increased 7.1% on an organic basis excluding Boston • Third quarter GAAP","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/917520/000091752023000069/0000917520-23-000069-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ending September 30, 2023"},{"label":"Revenue","value":"$382.4 million"},{"label":"Net income","value":"$19.5 million"},{"label":"EPS","value":"$0.24 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}